TY - JOUR
T1 - The neuroanatomical substrates of autism and ADHD and their link to putative genomic underpinnings
AU - Berg, Lisa M.
AU - Gurr, Caroline
AU - Leyhausen, Johanna
AU - Seelemeyer, Hanna
AU - Bletsch, Anke
AU - Schaefer, Tim
AU - Pretzsch, Charlotte M.
AU - Oakley, Bethany
AU - Loth, Eva
AU - Floris, Dorothea L.
AU - Buitelaar, Jan K.
AU - Beckmann, Christian F.
AU - Banaschewski, Tobias
AU - Charman, Tony
AU - Jones, Emily J.H.
AU - Tillmann, Julian
AU - Chatham, Chris H.
AU - Bourgeron, Thomas
AU - Ahmad, Jumana
AU - Ambrosino, Sara
AU - Auyeung, Bonnie
AU - Baron-Cohen, Simon
AU - Baumeister, Sarah
AU - Bölte, Sven
AU - Bours, Carsten
AU - Brammer, Michael
AU - Brandeis, Daniel
AU - Brogna, Claudia
AU - de Bruijn, Yvette
AU - Chakrabarti, Bhismadev
AU - Cornelissen, Ineke
AU - Crawley, Daisy
AU - Dell’Acqua, Flavio
AU - Dumas, Guillaume
AU - Durston, Sarah
AU - Faulkner, Jessica
AU - Frouin, Vincent
AU - Garcés, Pilar
AU - Goyard, David
AU - Ham, Lindsay
AU - Hayward, Hannah
AU - Hipp, Joerg
AU - Holt, Rosemary
AU - Johnson, Mark H.
AU - Kundu, Prantik
AU - Lythgoe, David J.
AU - Mason, Luke
AU - Ruggeri, Barbara
AU - Simonoff, Emily
AU - Ecker, Christine
N1 - Funding Information:
Open Access funding enabled and organized by Projekt DEAL. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI-JU2) under grant agreement No 115300 for the project EU-AUIMS and No 777394 for the project AIMS-2- TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. This work has received funding from Horizon Europe (Grant Agreement No. 101057385) and from UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee (Grant No. 10039383) (R2D2-MH). CE gratefully acknowledges support from the German Research Foundation (DFG) under the Heisenberg Programme (EC480/1-1 and EC480/2-1). DGM also acknowledges support from the NIHR Maudsley Biomedical Research Centre. DLF is supported by funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 101025785.
Funding Information:
The IMI-JU2 had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the IMI-JU2. Jan K. Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Takeda/Shire, Roche, Novartis, Medice, Angelini, and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. Tobias Banaschewski has served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, Otsuka, PCM scientific, Shire and Viforpharma. He received conference support or speaker’s fee by Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Shire and Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press. The present work is unrelated to the above grants and relationships. Julian Tillmann is a consultant for F. Hoffmann-La Roche Ltd. Chris H. Chatham is an employee of F. Hoffmann–La Roche. Tony Charman has received research grant support from the Medical Research Council (UK), the National Institute for Health Research, Horizon 2020 and the Innovative Medicines Initiative (European Commission), MQ, Autistica, FP7 (European Commission), the Charles Hawkins Fund, and the Waterloo Foundation. He has served as a consultant to F. Hoffmann-La Roche Ltd and Servier. He has received royalties from Sage Publications and Guilford Publications. Declan G. Murphy has received consultancy fees from Roche and Servier, and grant support from the Medical Research Council (UK), the National Institute for Health Research, Horizon 2020 and the Innovative Medicines Initiative (European Commission). Lisa M. Berg, Tim Schaefer, Caroline Gurr, Johanna Leyhausen, Hanna Seelemeyer, Charlotte M. Pretzsch, Bethany Oakley, Eva Loth, Dorothea L. Floris, Christian F. Beckmann, Emily J.H. Jones, Thomas Bourgeron, and Christine Ecker reported no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2023, BioMed Central Ltd., part of Springer Nature.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Autism spectrum disorders (ASD) are neurodevelopmental conditions accompanied by differences in brain development. Neuroanatomical differences in autism are variable across individuals and likely underpin distinct clinical phenotypes. To parse heterogeneity, it is essential to establish how the neurobiology of ASD is modulated by differences associated with co-occurring conditions, such as attention-deficit/hyperactivity disorder (ADHD). This study aimed to (1) investigate between-group differences in autistic individuals with and without co-occurring ADHD, and to (2) link these variances to putative genomic underpinnings. Methods: We examined differences in cortical thickness (CT) and surface area (SA) and their genomic associations in a sample of 533 individuals from the Longitudinal European Autism Project. Using a general linear model including main effects of autism and ADHD, and an ASD-by-ADHD interaction, we examined to which degree ADHD modulates the autism-related neuroanatomy. Further, leveraging the spatial gene expression data of the Allen Human Brain Atlas, we identified genes whose spatial expression patterns resemble our neuroimaging findings. Results: In addition to significant main effects for ASD and ADHD in fronto-temporal, limbic, and occipital regions, we observed a significant ASD-by-ADHD interaction in the left precentral gyrus and the right frontal gyrus for measures of CT and SA, respectively. Moreover, individuals with ASD + ADHD differed in CT to those without. Both main effects and the interaction were enriched for ASD—but not for ADHD-related genes. Limitations: Although we employed a multicenter design to overcome single-site recruitment limitations, our sample size of N = 25 individuals in the ADHD only group is relatively small compared to the other subgroups, which limits the generalizability of the results. Also, we assigned subjects into ADHD positive groupings according to the DSM-5 rating scale. While this is sufficient for obtaining a research diagnosis of ADHD, our approach did not take into account for how long the symptoms have been present, which is typically considered when assessing ADHD in the clinical setting. Conclusion: Thus, our findings suggest that the neuroanatomy of ASD is significantly modulated by ADHD, and that autistic individuals with co-occurring ADHD may have specific neuroanatomical underpinnings potentially mediated by atypical gene expression.
AB - Background: Autism spectrum disorders (ASD) are neurodevelopmental conditions accompanied by differences in brain development. Neuroanatomical differences in autism are variable across individuals and likely underpin distinct clinical phenotypes. To parse heterogeneity, it is essential to establish how the neurobiology of ASD is modulated by differences associated with co-occurring conditions, such as attention-deficit/hyperactivity disorder (ADHD). This study aimed to (1) investigate between-group differences in autistic individuals with and without co-occurring ADHD, and to (2) link these variances to putative genomic underpinnings. Methods: We examined differences in cortical thickness (CT) and surface area (SA) and their genomic associations in a sample of 533 individuals from the Longitudinal European Autism Project. Using a general linear model including main effects of autism and ADHD, and an ASD-by-ADHD interaction, we examined to which degree ADHD modulates the autism-related neuroanatomy. Further, leveraging the spatial gene expression data of the Allen Human Brain Atlas, we identified genes whose spatial expression patterns resemble our neuroimaging findings. Results: In addition to significant main effects for ASD and ADHD in fronto-temporal, limbic, and occipital regions, we observed a significant ASD-by-ADHD interaction in the left precentral gyrus and the right frontal gyrus for measures of CT and SA, respectively. Moreover, individuals with ASD + ADHD differed in CT to those without. Both main effects and the interaction were enriched for ASD—but not for ADHD-related genes. Limitations: Although we employed a multicenter design to overcome single-site recruitment limitations, our sample size of N = 25 individuals in the ADHD only group is relatively small compared to the other subgroups, which limits the generalizability of the results. Also, we assigned subjects into ADHD positive groupings according to the DSM-5 rating scale. While this is sufficient for obtaining a research diagnosis of ADHD, our approach did not take into account for how long the symptoms have been present, which is typically considered when assessing ADHD in the clinical setting. Conclusion: Thus, our findings suggest that the neuroanatomy of ASD is significantly modulated by ADHD, and that autistic individuals with co-occurring ADHD may have specific neuroanatomical underpinnings potentially mediated by atypical gene expression.
KW - ADHD
KW - ASD
KW - Comorbidity
KW - Imaging-genetics
KW - Neurodevelopmental disorders
KW - Structural MRI
UR - http://www.scopus.com/inward/record.url?scp=85173149559&partnerID=8YFLogxK
U2 - 10.1186/s13229-023-00568-z
DO - 10.1186/s13229-023-00568-z
M3 - Article
C2 - 37794485
AN - SCOPUS:85173149559
SN - 2040-2392
VL - 14
JO - Molecular Autism
JF - Molecular Autism
IS - 1
M1 - 36
ER -